Phase IIIB Subcutaneous Missed Dose Study

PHASE3CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

February 28, 2014

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Abatacept

Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)

DRUG

Placebo

Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)

Trial Locations (27)

1015

Local Institution, Capital Federal

2000

Local Institution, Rosario

3000

Local Institution, Santa Fe

4001

Local Institution, Berea

5000

Local Institution, Córdoba

7500

Local Institution, Panorama

9317

Local Institution, Bloemfontein

16508

Center For Assessment And Research Of Erie, Erie

16635

Altoona Center For Clinical Research, Duncansville

18015

East Penn Rheumatology Associates, Bethlehem

21502

Klein And Associates, M.D., Pa, Cumberland

26301

Mountain State Clinical Research, Clarksburg

29204

Columbia Arthritis Center, Columbia

34239

Sarasota Arthritis Research Center, Sarasota

37520

Local Institution, León

46227

Diagnostic Rheumatology And Research,Pc, Indianapolis

52140

Local Institution, Metepec

55121

St. Paul Rheumatology, P.A., Eagan

87102

Albuquerque Clinical Trials, Inc., Albuquerque

90048

Wallace Rheumatic Study Center, Los Angeles

97000

Local Institution, Mérida

06611

New England Research Associates, Llc, Trumbull

01610

Clinical Pharmacology Study Group, Worcester

G8Z 1Y2

Local Institution, Trois-Rivières

06726

Local Institution, Mexico City

0002

Local Institution, Muckleneuk

0084

Local Institution, Pretoria

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY